CGRP inhibitors

What are CGRP inhibitors?

Calcitonin gene-related peptide (CGRP) inhibitors block the effect of CGRP, which is a small protein that is highly prevalent in the sensory nerves that supply the head and the neck. CGRP is involved in pain transmission and levels increase during a migraine attack. It may also play a causative role in the induction of migraine attacks. CGRP inhibitors are used to manage migraines.

There are two types of CGRP inhibitors – monoclonal antibodies and CGRP receptor antagonists (gepants).

Monoclonal antibodies target either CGRP or the CGRP receptor and are used for migraine prevention. A monoclonal antibody is a collection of identical proteins that have been developed to only target one substance in the body. They are given by injection subcutaneously (under the skin), to avoid degradation by the stomach. Because they are large molecules, they take longer to start working and work in the lining of the brain rather than in the brain itself. They also tend to have few drug interactions and are unlikely to cause liver or kidney damage. The following monoclonal antibody CGRP inhibitors have been approved:

  • Aimovig (erenumab-aooe): Approved May 17, 2018
  • Ajovy (fremanezumab): Approved Sept 14, 2018
  • Emgality (galcanezumab-gnlm): Approved Sept 27, 2018
  • Vyepti (eptinezumab-jjmr): Approved Feb 21, 2020.

Gepants are small molecule drugs which block the CGRP receptor and are effective at both relieving migraines and preventing them. Unlike monoclonal antibodies, gepants rapidly penetrate the brain so work quickly; however, they are metabolized in the liver so there is a higher potential for interactions and possibly liver damage. The following have been approved to date:

  • Ubrelvy (ubrogepant): Approved Dec 23, 2019
  • Nurtec ODT (rimegepant sulfate): Approved Feb 27, 2020.
  • Qulipta (atogepant):  Approved Sept 28, 2021
  • Zavzpret (zavegepant) (intranasal/oral): Approved March 10, 2023.

CGRP inhibitors were the first drugs to be specifically developed for migraine prevention. All other migraine preventive agents were originally developed for other conditions (such as high blood pressure), and then found later by chance to have an effect in migraine. Triptans were developed to treat migraine attacks, although some have been used off-label as preventive agents, dosed continuously twice daily during the menstrual window, to treat menstrual migraines.

List drug with CGRP inhibitors

Drug Name
Aimovig
Generic name: Erenumab
Aimovig SureClick Autoinjector
Generic name: Erenumab
Ajovy
Generic name: Fremanezumab-vfrm
Atogepant
Generic name: Atogepant (a Toe' Je Pant)
Emgality
Generic name: Galcanezumab
Eptinezumab
Generic name: Eptinezumab
Eptinezumab-jjmr
Generic name: Eptinezumab-jjmr
Erenumab
Generic name: Erenumab
Erenumab-aooe
Generic name: Erenumab-aooe
Fremanezumab
Generic name: Fremanezumab
Fremanezumab-vfrm
Generic name: Fremanezumab-vfrm
Galcanezumab
Generic name: Galcanezumab
Galcanezumab-gnlm
Generic name: Galcanezumab-gnlm
Nurtec ODT
Generic name: Rimegepant
Qulipta
Generic name: Atogepant
Rimegepant
Generic name: Rimegepant
Ubrelvy
Generic name: Ubrogepant
Ubrogepant
Generic name: Ubrogepant
Vyepti
Generic name: Eptinezumab-jjmr (injection, For Intravenous Use)
Zavegepant
Generic name: Zavegepant
Zavegepant nasal
Generic name: Zavegepant Nasal
Zavzpret
Generic name: Zavegepant

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords